2011年 12月 11日: 早坂章

Today, I would like you to intoduce the guidelines of the treatment of hepatis B and hepatitis C in Japan in English.

This draft is uploaded on slideshare.net.

Originally, I was asked to write this short article via LinkedIn.

When I submitted this draft, I was told that the publisher changed their mind to publish the magazine.

Then, this article remins unpublished.

I know that my English draft is quite poor, but I thought that some people who do not read Japanese may have some interest on the Japanase guidelines for the treatment of hepatitis B and C.

You can read and download this pdf file from the following URI.

An introduction of the treatment guidelines for hepatitis B and C in Japan

I hope that this short report help someone to know the situation in Japan.

未発表原稿です。依頼を受けてまとめましたが、本当か、だまされたのか、雑誌は出版社の都合で中止と連絡を受けました。内容がまずからかもしｔれませんが、日本語を読まれない方に、日本の治療ガイドラインの紹介をさせていただければ、嬉しいです。

千葉県木更津市　肝臓内科　肝炎治療の「はやさかクリニック」　院長　肝臓専門医　早坂章

2011年 07月 29日: 早坂章

千葉県木更津市　肝臓内科　消化器科　内科　はやさかクリニック　院長　肝臓専門医　早坂章です。

先ほどの記事で、ホワイトハウスへのリンクが貧弱ですみませんでした。

White House Commemorates World Hepatitis Day 2011

大統領声明

です。

　

2011年 07月 29日: 早坂章  

みなさん、ごぶさたしております。

千葉県木更津市　肝臓内科　消化器科　内科　肝炎治療に力をそそいでいる　はやさかクリニック　院長　肝臓専門医　早坂章です。

昨日、7月28日はWHOが定めた第一回目の世界肝炎デーでした。

WHO　ホワイトハウス、また、日本の厚生労働省も肝炎についての意識の向上を目指し、様々な企画を実践したようです。

米国のオバマ大統領も　声明を発表し、web上で、その声明文のｐｄｆ　ファイルが閲覧できます。

私は7月24日に千葉県木更津市で、市民公開講座　「B型肝炎C型肝炎の最新治療について」の演者をつとめました。

来年の世界肝炎デーに向けて、準備したいと思います。

2011年 05月 29日: 早坂章  

千葉県木更津市　はやさかクリニック　院長　肝臓専門医　早坂章です。米国肝臓学会では、FDAがC型肝炎治療薬、2剤を認可したと発表しました。

使用適応に関する注意がきちんと書かれています。　日本語訳はのちほどで申し訳ありません。

The FDA has just approved two direct-acting antivirals for the treatment of hepatitis C (HCV): boceprevir and telaprevir.

Each of them improves cure rates in selected patients infected with HCV genotype 1 — when used in combination with pegylated interferon and ribavirin. Approved treatment schedules will be complex and different for each of them. AASLD will soon release updated treatment guidelines for hepatitis C that will include specifics of therapy with each of these drugs.

In the meantime, the following are important issues regarding these drugs:

1. Neither drug can be used alone. Each of them can only be used in combination with pegylated interferon and ribavirin. When used alone, the drug will not be effective and will cause emergence of antiviral-resistant mutants that could be difficult to treat subsequently.
2. They are only approved for use in patients with HCV genotype 1.
3. They are not approved for use in post-transplant recurrent HCV.
4. They are not approved for use in HIV/HCV coinfected patients.
5. They are not approved for use in children.
6. The newly approved treatment schedules have more side effects than pegylated interferon and ribavirin, and should be managed carefully.

An announcement will be made as soon as the updated AASLD guidelines are available.

2011年 05月 29日: 早坂章

 

千葉県木更津市　はやさかクリニック　院長　肝臓専門医　早坂章です。

米国でC型肝炎治療薬が2剤認可になりましたが、telaprevirについてのFDAの発表です。　まず、英語でひとつ御紹介です。

FDA NEWS RELEASE

For Immediate Release: May 23, 2011
Media Inquiries: Erica Jefferson, 301-796-4988, erica.jefferson@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA

FDA approves Incivek for hepatitis C

The U.S. Food and Drug Administration today approved Incivek (telaprevir) to treat certain adults with chronic hepatitis C infection. Incivek is used for patients who have either not received interferon-based drug therapy for their infection or who have not responded adequately to prior therapies. Incivek is approved for use with interferon therapy made up of peginterferon alfa and ribavirin.

The current standard of care for patients with chronic hepatitis C infection is peginterferon alfa and ribavirin taken for 48 weeks. Less than 50 percent of patients respond to this therapy.

The safety and effectiveness of Incivek was evaluated in three phase 3 clinical trials with about 2,250 adult patients who were previously untreated, or who had received prior therapy. In all studies patients also received the drug with standard of care. In previously untreated patients, 79 percent of those receiving Incivek experienced a sustained virologic response (i.e. the infection was no longer detected in the blood 24 weeks after stopping treatment) compared to standard treatment alone.

The sustained virologic response for patients treated with Incivek across all studies, and across all patient groups, was between 20 and 45 percent higher than current standard of care.

The studies indicate that treatment with Incivek can be shortened from 48 weeks to 24 weeks in most patients. Sixty percent of previously untreated patients achieved an early response and received only 24 weeks of treatment (compared to the standard of care of 48 weeks). The sustained virologic response for these patients was 90 percent.

When a person achieves a sustained virologic response after completing treatment, this suggests that the hepatitis C infection has been cured.

Sustained virologic response can result in decreased cirrhosis and complications of liver disease, decreased rates of liver cancer (hepatocellular carcinoma), and decreased mortality.

“With the approval of Incivek, there are now two important new treatment options for hepatitis C that offer a greater chance at a cure for some patients with this serious condition,” said Edward Cox, M.D., M.P.H, director, Office of Antimicrobial Products in FDA’s Center for Drug Evaluation and Research. “The availability of new therapies that significantly increase responses while potentially decreasing the overall duration of treatment is a major step forward in the battle against chronic hepatitis C infection.”

According to the U.S. Centers for Disease Control and Prevention, about 3.2 million people in the United States have chronic hepatitis C infection, a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure.
Most people with hepatitis have no symptoms of the disease until liver damage occurs, which may take several years.

Most liver transplants performed in the United States are due to progressive liver disease caused by hepatitis C virus infection. After the initial infection with hepatitis C (HCV), most people develop chronic hepatitis C. Some will develop cirrhosis of the liver over many years. Cirrhosis can lead to liver damage with complications such as bleeding, jaundice (yellowish eyes or skin), fluid accumulation in abdomen, infections, or liver cancer.

People can get HCV in a number of ways, including: exposure to blood that is infected with the virus; being born to a mother with HCV; sharing a needle; having sex with an infected person; sharing personal items such as a razor or toothbrush with someone who is infected with the virus, or from unsterilized tattoo or piercing tools.

Incivek is a pill taken three times a day with food. Incivek should be taken for the first 12 weeks in combination with peginterferon alfa and ribavirin. Most people with a good early response to the Incivek combination regimen can be treated for 24 weeks rather than the recommended 48 weeks of treatment with the standard of care. Incivek is part of a class of drugs referred to as protease inhibitors, which work by binding to the virus and preventing it from multiplying.

The most commonly reported side effects in patients receiving Incivek in combination with peginterferon alfa and ribavirin include rash, low red blood cell count (anemia), nausea, fatigue, headache, diarrhea, itching (pruritus), and anal or rectal irritation and pain. Rash can be serious and can require stopping Incivek or all three drugs in the treatment regimen.

On May 13, FDA approved Victrelis (boceprevir), another new treatment for chronic hepatitis C, marketed by Merck of Whitehouse Station, N.J.

Incivek is marketed by Cambridge, Mass.-based Vertex Pharmaceuticals.